4SC AG EV/Sales
Was ist das EV/Sales von 4SC AG?
EV/Sales von 4SC AG ist N/A
Was ist die Definition von EV/Sales?
Enterprise value to sales ratio compares a company’s total value to its sales.
ttm (trailing twelve months)
Enterprise value/sales is a valuation ratio that compares the company's enterprise value to its annual sales. It indicates the company's capacity to generate free cash flow. In general, the lower the ratio, the cheaper the company is.
EV/Sales is most often calculated as cash and cash equivalents subtracted from the sum of market capitalization and debt and divided by annual sales. Many analysts consider EV/sales to be a more accurate metric than Price/Sales as it considers both debt and equity holders in its calculation. One of the limitations of the calculation is that sales do not take into account a company's taxes or expenses.
EV/Sales von Unternehmen in Health Care Sektor auf XETRA im Vergleich zu 4SC AG
Was macht 4SC AG?
4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company's products in clinical development stage include Resminostat, an orally administered histone deacetylase inhibitor that is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma; and Domatinostat, an orally administered small molecule, which is in Phase Ib/II clinical trial for the treatment of melanoma and Phase II clinical trial for the treatment of gastrointestinal tumor. 4SC AG also out-licenses its products to pharma and biotech companies for the treatment of cancer. The company has a collaboration agreement with the Netherlands Cancer Institute to evaluate Domatinostat in the neoadjuvant setting in melanoma. 4SC AG was founded in 1997 and is headquartered in Planegg, Germany.
Unternehmen mit ev/sales ähnlich 4SC AG
- Xenetic Biosciences Inc hat EV/Sales von N/A
- Third Point Offshore Investors hat EV/Sales von N/A
- AIB plc hat EV/Sales von N/A
- Primorus Investments plc hat EV/Sales von N/A
- Arowana Australasian Value Opportunities Fund Ltd hat EV/Sales von N/A
- ReNeuron plc hat EV/Sales von N/A
- 4SC AG hat EV/Sales von N/A
- Royal Bank of Scotland Plc hat EV/Sales von N/A
- RiverNorth Flexible Municipal Income Fund Inc hat EV/Sales von N/A
- Pulmatrix Inc hat EV/Sales von N/A
- EML Payments hat EV/Sales von N/A
- Independent Investment Trust Plc hat EV/Sales von N/A
- Dividend 15 Split II hat EV/Sales von N/A